Mathai Mammen - 03 Jan 2022 Form 3 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Pharm, R&D
Signature
Raavi Deol, as attorney-in-fact for Mathai Mammen
Issuer symbol
JNJ
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
3
Filing time
13 Jan 2022, 15:43:13 UTC
Previous filing
15 Jun 2021
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JNJ Common Stock 32,477 03 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JNJ Employee Stock Options (Right to Buy) 03 Jan 2022 Common Stock 28,927 $129.51 Direct F1
holding JNJ Employee Stock Options (Right to Buy) 03 Jan 2022 Common Stock 36,098 $131.94 Direct F1
holding JNJ Employee Stock Options (Right to Buy) 03 Jan 2022 Common Stock 58,130 $151.41 Direct F1
holding JNJ Employee Stock Options (Right to Buy) 03 Jan 2022 Common Stock 43,149 $164.62 Direct F1
holding JNJ Restricted Share Units 03 Jan 2022 Common Stock 35,951 Direct F2
holding JNJ Restricted Share Units 03 Jan 2022 Common Stock 3,929 Direct F2
holding JNJ Restricted Share Units 03 Jan 2022 Common Stock 4,545 Direct F2
holding JNJ Restricted Share Units 03 Jan 2022 Common Stock 7,418 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vested and exercisable on the third anniversary of the date of the grant.
F2 Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock and vests on the third anniversary of the date of grant.

Remarks:

mammenpoa1.txt